Revvity to Acquire Human Cell Design, Bolstering Metabolic Disease Drug Discovery
RVTY sits 55% above its 52-week low of $81.22.
Summary
Revvity is acquiring Human Cell Design, a specialist in human-relevant cell models for metabolic disease drug discovery. The deal strengthens Revvity's position in the high-growth metabolic disease research market, aligning with its life sciences strategy. No financial terms were disclosed, but the acquisition adds differentiated technology and likely complements existing offerings. This follows a strong Q2 where Revvity beat estimates and raised guidance, suggesting continued investment in growth areas. Watch for integration details and any impact on near-term earnings.
At the time of this announcement, RVTY was trading at $126.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $14.2B. The 52-week trading range was $81.22 to $133.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.